Corporate Profile

CalciMedica is a clinical-stage biopharmaceutical company focused on developing first-in-class therapies for life-threatening inflammatory diseases with high unmet need. CalciMedica’s proprietary technology targets the inhibition of CRAC channels designed to modulate the immune response and protect against tissue cell injury, with the potential to provide therapeutic benefits in life-threatening inflammatory diseases for which there are currently no approved therapies.

Learn More

Stock Information

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Featured Events

View all Events

Featured Reports

View all Reports

Press Releases

21 Sep 23

CalciMedica Acute Pancreatitis Clinical Experts Event

Listen to the Webcast

 06 Sep 23

CalciMedica Announces Upcoming Presentations and Events in September

LA JOLLA, Calif. , Sept. 6, 2023 /PRNewswire/ -- CalciMedica Inc. (" CalciMedica ") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic
31 Aug 23

CalciMedica to Host Acute Pancreatitis Clinical Experts Event on September 21, 2023

LA JOLLA, Calif. , Aug. 31, 2023 /PRNewswire/ -- CalciMedica Inc. (" CalciMedica ") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic
10 Aug 23

CalciMedica Reports Second Quarter 2023 Financial Results and Provides Clinical & Corporate Updates

International expansion of CARPO, a Phase 2b clinical trial of Auxora in acute pancreatitis (AP) patients with accompanying systemic inflammatory response syndrome (SIRS), in India Expansion of team with key leadership appointments in regulatory and clinical development Filing of an investigational
View all Releases
Explore More
Our Technologies
Our Pipeline
Our Story
Our Team